pMHC-targeted TCRm Antibody Optimization

Solutions

Online Inquiry

Most research on pMHC-targeted TCRm antibodies has been conducted in the field of cancer as a new tool. By combining the T cell specificity of recognizing pMHC complexes with the pharmacological properties of antibodies, TCRm antibodies may have a wide range of clinical applications. However, the development of pMHC-targeted TCRm antibodies is hampered by the fact that they are MHC-restricted, occurrence of immune evasion and the immunosuppressive environment.

In order for TCRm antibodies to achieve clinical success, we need to overcome these obstacles and optimize TCRm antibodies for ideal cancer immunotherapy. Creative BioMart provides optimization solutions for TCRm antibodies, applying various strategies to enhance the potency of TCRm antibodies and maximize their benefits in subsequent applications.

Challenges in the Development of pMHC-targeted TCRm Antibody

Challenges in the development of pMHC-targeted TCRm antibody - Creative BioMart

Compared to TCR antibodies, TCRm antibodies have a higher affinity for pMHC and maintain all the advantages of antibodies, such as stability, high yield and a well-established production system. In addition, anti-TCRm antibodies can be produced simply and efficiently by in vitro operations such as animal immunization and hybridoma techniques. However, a number of challenges must be overcome in order for TCR-like antibodies to be successfully used in the clinical setting.

MHC restriction of TCRm antibody. TCRm antibodies are only effective against tumor-specific antigens expressed on specific MHC alleles. There are still many MHC alleles that lack tumor-specific peptides, which hinders the development of TCRm antibody therapies.
Immune surveillance evasion of tumor cells. Down-regulation or absence of the pMHC complex on the tumor cell surface causes tumor cells to evade immune surveillance, thus affecting the effect of TCRm antibodies.

Immunosuppressive environments. Tumor cells are surrounded by many suppressive immune cells that inhibit antitumor immune responses, so TCRm antibodies may bind to pMHC complexes but not mediate tumor destruction.

Our Solutions

TCRm antibodies play an important role in detecting the expression of tumor-specific pMHC complexes on the surface of tumor cells and in mediating cytotoxicity to tumor cells. We offer specific optimized solutions for TCRm antibodies to enhance the efficacy and expand the scope of applications.

TCRm antibodies are coupled with fluorescent reagents. To measure the expression levels of pMHC complexes on the surface of tumor cells, providing valuable information for the selection of immunotherapeutic targets.
TCRm antibodies are converted into CAR structures. To mediate tumor-specific lysis of T cells.
TCRm antibodies bind to toxins or drugs. To specifically lyse tumor cells.
TCRm antibodies bind to secondary antibodies. To specifically activate immune cells.
TCRm antibodies induce the function of ADCC, CDC and ADCP. To induce direct tumor cell death upon binding to pMHC complexes.

Applications

Our services are designed to help clients address the specific challenges of TCRm antibody applications, including

Inadequate MHC antigen presentation
Lack of MHC internalization
Cross-reactivity with other epitopes

Creative BioMart will open up project optimization solutions for TCRm antibody-based intracellular antigen targeting and precision tumor therapy, please contact us to learn more about our services.

Reference

He Q, et al. "TCR-like antibodies in cancer immunotherapy." J Hematol Oncol (2019),12(99).

For research use only. Not for clinical use.